ClinicalTrials.gov
public full text
Public Domain
Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
In this study,288 adult migraine patients aged 18-65 years (diagnosed with migraine without aura and/or migraine with aura, with at least a 1-year history)will be collected to evaluate the efficacy, safety and tolerability of Anisodine Hydrobromide in preventing migraine attacks in episodic migraine in adults.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention#1340362
- Migraine in children and adolescents.#662839
- Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults#892351
- Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old#1195606
- Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine#1093040
Record · ID 1384439
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive